Tirzepatide hits two receptors instead of one, GIP and GLP-1, which suppresses appetite and improves insulin sensitivity, each through its own pathway. Clinical trials showed it beats semaglutide on raw weight loss numbers (22.5% vs 15%), and people generally report less nausea. The branded versions are Mounjaro (for type 2 diabetes) and Zepbound (for obesity). Compounded tirzepatide is the same molecule sourced from compounding pharmacies, typically as a lyophilized powder or pre-mixed vial. The titration matters just as much as with sema. Start at 2.5mg, hold each dose for at least 4 weeks, and your gut will cooperate better than if you rush it.
Tirzepatide Protocol
Dose: 2.5mg-15mg per week (titrated up) | Frequency: Once weekly | Cycle: Ongoing (not cycled) | Route: SubQ
Start at 2.5mg for 4 weeks minimum before increasing. Each dose level should be held for at least 4 weeks. The titration is slower than sema but the GI tolerance is usually better.
Tirzepatide Effects
Weight loss (90%). Up to 22.5% body weight reduction in 72-week trials, with nearly two-thirds of participants losing 20%+ at the highest dose
Appetite suppression (88%). Dual-receptor activation means your body actually feels done eating. Not willpower. Done.
Improved insulin sensitivity (72%). Blood sugar and A1C improve even if you're not diabetic. Your pancreas says thank you.
Waist circumference reduction (80%). About 5 inches off your waist in clinical trials. That's a pants size.
Tirzepatide Side Effects
Nausea (31%). Lower nausea rates than sema, but still the most common side effect. Worst during dose bumps, then it settles.
Diarrhea (23%). Can hit at any dose level. Stays mild for most people. Hydrate more than you think you need to.
Constipation (18%). Less common than with sema but still happens. Fiber, water, maybe magnesium.
Vomiting (12%). Usually only when the dose goes up. Smaller meals help a lot. Your stomach is working differently now.
Injection-site reactions (7%). Mild red spot or some itching where you pinned. Nothing serious.
Tirzepatide Dosing by Use Case
Condition
Dose
Duration
Notes
Weight loss (primary indication)
2.5mg to 15mg weekly, titrated
Ongoing, minimum 24 weeks for meaningful results
Start at 2.5mg. Hold each dose for 4 weeks minimum. Titrate to 5mg, 7.5mg, 10mg, 12.5mg, 15mg. Most people find their sweet spot between 7.5-10mg. Don't rush the titration. Your gut will punish you.
Type 2 diabetes management
2.5mg to 15mg weekly, titrated
Ongoing
FDA-approved as Mounjaro for this indication. A1C reductions of 1.87-2.07% in SURPASS trials. If you're on insulin or sulfonylureas, your prescriber needs to adjust those down to avoid low blood sugar.
Metabolic syndrome and insulin resistance
2.5mg to 10mg weekly
Ongoing
Tirzepatide improves insulin sensitivity through both GIP and GLP-1 pathways. Fasting glucose, triglycerides, and blood pressure all trend down. Some people plateau at 5-7.5mg for metabolic benefits without needing the higher doses used for aggressive weight loss.
Visceral fat reduction
5mg to 15mg weekly
16+ weeks
Tirzepatide reduces visceral fat more effectively than semaglutide in head-to-head data. The waist circumference reductions are dramatic. Some protocols add tesamorelin for targeted visceral fat, though tirzepatide already hits it hard on its own.
Tirzepatide Results Timeline
Week 1-4, 2.5mg adjustment: Appetite starts shifting. You might notice you forget about snacks. Mild nausea is common during the first week, then settles. Some constipation. This dose is about tolerance, not results. Don't skip it.
Week 4-8, 5mg, appetite really drops: This is where most people feel it. Portion sizes shrink naturally. Food noise quiets down. 2-4% body weight loss is typical by week 8. GI side effects may spike briefly after the dose increase, then settle again.
Week 8-16, 7.5-10mg, peak weight loss rate: Fastest rate of weight loss. 1-2% body weight per month is common. Waist circumference visibly changing. Energy usually improves as metabolic function normalizes. Watch protein intake. Your body will pull from muscle if you don't eat enough protein.
Week 16+, 10-15mg, maintenance phase: Weight loss slows as you approach a new equilibrium. Some people hold at 10mg long-term. Others push to 15mg for the last stretch. The SURMOUNT-4 trial showed weight regain after stopping, so most protocols are indefinite. That's the honest reality.
Frequently Asked Questions About Tirzepatide
What is compounded tirzepatide?
Compounded tirzepatide is the same active molecule as Mounjaro and Zepbound, prepared by compounding pharmacies instead of Eli Lilly. It typically comes as a lyophilized powder (you reconstitute with bacteriostatic water) or a pre-mixed liquid vial. The molecular structure is identical. The difference is manufacturing oversight: branded versions are FDA-inspected, compounded versions are regulated by state pharmacy boards. Compounded tirzepatide became widely available during the FDA-declared shortage of Mounjaro/Zepbound.
What is the tirzepatide dosage schedule?
Start at 2.5mg once weekly for at least 4 weeks. Then increase to 5mg weekly for 4 weeks. Continue titrating up in 2.5mg increments (7.5mg, 10mg, 12.5mg, 15mg) with at least 4 weeks at each level. Most people find their effective dose between 7.5-10mg. The maximum is 15mg weekly. Rushing the titration causes worse nausea and GI side effects. If you're using compounded tirzepatide from a vial, use our calculator to convert mg doses to syringe units based on your vial concentration.
What are the side effects of tirzepatide?
Nausea (31%), diarrhea (23%), constipation (18%), vomiting (12%), and injection-site reactions (7%). GI side effects are worst during dose increases and usually settle within 1-2 weeks at each new dose. Tirzepatide has lower nausea rates than semaglutide in head-to-head trials (SURPASS-2). Smaller meals, eating slowly, and avoiding fatty foods help. Serious but rare: pancreatitis, gallbladder issues, and potential thyroid concerns (boxed warning for a rare thyroid cancer (showed up in rats, not confirmed in humans)).
How does tirzepatide compare to semaglutide?
Tirzepatide hits two receptors (GIP + GLP-1) vs semaglutide's one (GLP-1 only). In head-to-head trials, tirzepatide produced more weight loss (22.5% vs ~15%) and better A1C reductions. GI side effects were similar or slightly lower with tirzepatide. Tirzepatide costs more. Both are dosed weekly via SubQ injection. The practical difference most people notice: tirzepatide suppresses appetite more aggressively, and the nausea profile is slightly more manageable.
How does tirzepatide work?
Tirzepatide is a dual GIP/GLP-1 receptor agonist. GLP-1 slows down how fast your stomach empties, reduces appetite, and increases insulin secretion. GIP enhances the GLP-1 effect and may improve fat metabolism directly. Together, they produce stronger appetite suppression and better metabolic results than hitting either receptor solo. The dual agonist mechanism is why tirzepatide outperforms semaglutide (GLP-1 only) in clinical trials.
How do you reconstitute compounded tirzepatide?
For a 10mg lyophilized vial: add 2mL of bacteriostatic water. That gives you 5mg per mL. For a 2.5mg dose, draw 50 units (0.5mL) on a U-100 insulin syringe. For 5mg, draw 100 units (1mL). Aim the water at the glass wall, not directly on the powder. Swirl gently. Never shake. If your compounded tirzepatide comes pre-mixed, check the concentration on the label and use our calculator to determine the correct units.
How much weight can you lose on tirzepatide?
In the SURMOUNT-1 trial, participants lost an average of 22.5% of body weight at the 15mg dose over 72 weeks. That's roughly 50-60 pounds for someone starting at 250 lbs. Nearly two-thirds of participants on the highest dose lost 20% or more. Real-world results vary. Diet, exercise, starting weight, and how high you titrate all matter. Weight regain after stopping is common (the SURMOUNT-4 trial confirmed this), which is why most protocols are indefinite.
Is tirzepatide safe?
Tirzepatide is FDA-approved, which means it passed large-scale safety trials (SURPASS and SURMOUNT programs, thousands of participants). Common side effects are GI-related and mostly manageable. Rare but serious risks include pancreatitis, gallbladder disease, and a theoretical thyroid cancer risk (observed in rodents, not confirmed in humans). It's contraindicated if you have a personal or family history of a rare thyroid cancer or MEN2 (a hereditary endocrine condition). For compounded versions, the safety of the molecule is the same. The variable is manufacturing quality. Always verify your compounding pharmacy is accredited.
Strong evidence. FDA-approved as Mounjaro (diabetes) and Zepbound (obesity). The SURMOUNT trials showed up to 22.5% body weight loss, more than semaglutide in head-to-head comparisons. Dual mechanism (GIP + GLP-1) appears to cause fewer GI side effects than GLP-1 alone.
Approval status: FDA-approved (branded)
References
Rosenstock J, Wysham C, Frias JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet, 2021. PMID 34186022
Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med, 2021. PMID 34170647
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med, 2022. PMID 35658024
Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet, 2023. PMID 37385275
Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). N Engl J Med, 2023. PMID 37840095
Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA, 2024. PMID 38078870
Storage
Lyophilized: Refrigerate at 2-8C. Stable for 6+ months sealed.
Reconstituted: Refrigerate. Use within 28 days.
Water: Bacteriostatic water, 2mL per 10mg vial for compounded versions.
Needle: 30-31 gauge, 0.5 inch for subcutaneous injection
These statements have not been evaluated by the FDA. This content is for educational purposes only. Consult a healthcare professional before starting any protocol. vialprep sells injection supplies, not compounds.
